Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny Inc. has demonstrated strong performance in its egg retrieval and banking services, with a record 39% year-over-year increase, driven by heightened demand among women in the tech industry amid economic uncertainties. The company's anticipated standardization of coverage packages for fertility benefits is expected to yield incremental revenue opportunities, particularly as more states implement IVF mandates. Additionally, robust client retention rates near 100% and an increase in covered lives accessing ancillary services from 1.5 million in 2025 to 2.7 million in 2026 further solidify Progyny's growth potential and positive outlook for future financial performance.

Bears say

Progyny Inc. is facing significant headwinds due to ongoing economic uncertainty and a weak jobs market, which may deter potential clients from utilizing its fertility and pharmacy benefit offerings. Furthermore, the company's reduction in expected covered lives from 7.6 million to 7.2 million combined with lower adjusted EBITDA guidance—ranging from $224 to $239 million—suggests a decline in revenue potential that does not meet previous estimates. Additionally, the competitive landscape presents challenges for maintaining market share, as underperformance could adversely affect the company's overall operational results.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.